Fannie Mae-No Politics (FNMA): You keep on arguing points I never made....

Guido2 · 2022-08-27T02:49:52.4670000Z

You keep on arguing points I never made. I didn't ever say that Fisher's lawsuits are anything other than what they are. Derivative claims for NWS above the 10% dividend and the wrIte down of the SPS to zero. Here's his latest on this subject. https://mobile.twitter.com/bryndonfisher/status/1514321109969096704 If Kelly wins his derivative claim, the corporations get back $110 billion. What does that mean? Would the dividends still be in effect? Wouldn't it result in similar suits. Why would the government be allowed to retain the warrants? Isn't that a taking? etc, etc. I rather not have these pointless discussions with you. Just a waste of time.

Play Episode

6min

Proactive - Interviews for investors

Itaconix CEO on 2025 strategy and profitability goals

Itaconix PLC (AIM:ITX, OTCQB:ITXXF) CEO John Shaw joined Steve Darling from Proactive to provide an update on the company’s progress following its strategic restructuring and to discuss what lies ahead for 2025. Shaw highlighted that the company ended 2024 with strong momentum, achieving nearly $3.7 million in revenue in the second half, marking one of its highest-ever earnings periods. The restructuring initiative focused on enhancing profitability, with a significant emphasis on reshaping the customer base. Shaw noted, “We actually increased our gross profit margin from about 31% to almost 35% last year.” Despite experiencing lower revenue in some areas, the company was able to maintain steady gross profits due to its emphasis on margin improvement. Shaw also discussed significant product developments, including the launch of Itaconix TSI 422, a new detergent ingredient that is gaining traction in North America and Europe. He further explained how the SPARX program, introduced in October, is helping accelerate customer collaboration in key product categories, positioning the company for continued growth. In addition to product development, the company has made strategic investments in its operations, marketing, and regulatory capabilities to support its growth trajectory. Shaw expressed confidence in the company’s production team and infrastructure, stating, “We really have everything in place we need right now to have a great run over the next 24 months.” While tariffs remain a consideration, Shaw believes any impacts will be manageable, and in some cases, could even be beneficial to the company. #proactiveinvestors #itaconixplc #aim #itx #otcqb #itxxf #SustainableChemicals #CleanTech #TSI422 #SPARXProgram #SpecialtyChemicals #JohnShaw #InvestorUpdates #ProactiveInvestors #GreenChemistry #DetergentInnovation #GrossProfitMargins #RestructuringSuccess

Proactive - Interviews for investors

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones

Trevi Therapeutics CEO Jennifer Good joined Steve Darling from Proactive to discuss the company’s progress in advancing its cough treatment pipeline using nalbuphine, a mixed agonist-antagonist opioid. Originally developed for acute indications, nalbuphine is now being repurposed due to its dual mechanism of action, working both peripherally in the lungs and centrally in the brainstem, offering a novel approach to treating chronic cough disorders. Trevi initially explored multiple indications, including skin conditions caused by severe itching and neurological cough. However, compelling clinical data led the company to focus on cough-related indications. Good explained, “We thought our drug was different because not only does it work peripherally in the lung, it works centrally at the brain, which mediates coughing and breathing.” The company is now targeting three key areas: interstitial lung diseases (including idiopathic pulmonary fibrosis, or IPF), refractory chronic cough (RCC), and other neurological cough conditions. Following promising Phase 2a results in RCC—an area where many previous drug candidates have failed—Trevi is preparing for a Phase 2b dose-ranging study. If successful, only one pivotal study may be required before regulatory filing. Good also highlighted Trevi’s strong financial position, noting that the company has sufficient cash runway to support its current studies through the second half of 2026, including further development in RCC and IPF. #proactiveinvestors #trevitherapeuticsinc #nasdaq #trvi #JenniferGood #Nalbuphine #ChronicCough #RefractoryCough #Phase2aResults #BiotechNews #PharmaPipeline #IPF #ClinicalTrials #CoughTreatment #NeurologicalDisorders #ProactiveInvestors

Proactive - Interviews for investors

Andromeda Metals nears funding milestone for Great White Project

Andromeda Metals Ltd acting CEO Sarah Clarke talked with Proactive about the company's progress on its flagship Great White Project in South Australia. Clarke outlined how the company is nearing a critical funding milestone, having entered into exclusive negotiations with Merricks Capital for a debt financing facility of up to $75 million. She explained that this follows detailed due diligence and represents a significant advancement in the project’s development. She noted that the facility would cover capitalised interest, fees, and a cost overrun tranche, with exclusivity on negotiations running through to the end of July. Clarke also said Andromeda is pursuing the balance of required funds through a parallel equity or investment process. The Great White Project is a high-grade kaolin operation targeting premium ceramic markets and sustainable concrete products. The company has all key approvals in place, feasibility studies completed, long-lead items ordered, and binding offtake agreements secured for its Stage 1A+ development, which involves 100,000 tonnes of kaolin production per annum. Clarke said the project team is fully mobilised, working across both operational readiness and financing, to ensure rapid commencement of construction once funding is secured. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #AndromedaMetals #GreatWhiteProject #Kaolin #MiningAustralia #CriticalMinerals #CeramicsIndustry #GreenConcrete #ProjectFinancing #MerricksCapital #ProactiveInvestors

Proactive - Interviews for investors

Element 25 delivers positive Tokyo Bay Scoping Study

Element 25 managing director Justin Brown talked with Proactive about the recent completion of the Tokyo Bay HPMSM Facility Scoping Study in partnership with Nissin Chemical Corporation. The company said the results of the scoping study were positive enough to justify advancing the project to the pre-feasibility stage. Brown explained that the Tokyo Bay site offers unique advantages, including a co-located sulfuric acid plant, deepwater port access, and supporting infrastructure critical for high-purity manganese sulfate production. “We took our learnings from the detailed work we’ve done in Louisiana… and converted them to a Japanese setting,” Brown said. He also noted that Japan's regulatory and geopolitical environment makes it an ideal location for refining and supplying the local battery market. Looking ahead, Brown confirmed that Element 25 and Nissin Chemical will conduct deeper engineering and cost analysis under their existing MOU, with a final investment decision targeted for June 2026. The next milestone will be the pre-feasibility study, expected later this year. Brown also discussed how the Tokyo Bay project fits into the company’s broader “design one, build many” strategy, which aims to establish a global network of refineries fed by ethically sourced manganese from Element 25’s Butcherbird mine. In addition to activity in Japan, Brown highlighted ongoing work in Europe and updates on the Butcherbird expansion and Louisiana project, with construction planned to commence later this year. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications so you never miss an update. #Element25 #Manganese #BatteryMetals #TokyoBay #CriticalMinerals #EVSupplyChain #HPMSM #ButcherbirdProject #CleanEnergyMaterials #JapanRefinery #MiningNews #GreenMetals #ProactiveInvestors

Followers	37
Posts	9914
Boards Moderated	0
Alias Born	08/08/2016

Volume:	246
Day Range:
Bid:	5.75
Ask:	5.92
Last Trade Time:	8:00:02 AM EDT
Total Trades:	2

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

FNMA Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free